Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma

NCT01552967 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Adenocarcinoma

Interventions

DRUG: Capecitabine

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University